HLS Therapeutics Inc

TSX:HLSCanadaView on OTC Pink - Current Information

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.

Contact Information

Headquarters

10 Carlson Court, Suite 701ETOBICOKE, ON, Canada M9W 6L2

Phone

647-495-9000

Fax

647-495-9000

Executives

Independent Chairman of the Board

John Welborn

Chief Executive Officer, Director

Craig Millian

Interim Chief Financial Officer, Director

John Hanna

Senior Vice President - Legal, HR and Compliance, Corporate Secretary

Ryan Lennox

Senior Vice President - Commercial

Brian Walsh